Literature DB >> 1534713

Pharmacokinetics and pharmacodynamics of amlodipine.

D R Abernethy1.   

Abstract

Amlodipine is a low-clearance, dihydropyridine calcium antagonist. The slow rate of elimination (elimination half-life of 40-60 h) confers several pharmacokinetic characteristics that are not seen with other calcium-antagonist drugs. It has high oral bioavailability (60-80%) and accumulates to a steady-state with once-daily administration over a period of 1-1 1/2 weeks. Fluctuation of plasma drug concentration between doses is between 20 and 25% when once-daily dosing is used. Onset of effect is gradual after oral administration which is due, in part, to an intermediate rate of drug absorption (peak plasma drug concentration occurs 6-8 h after dosing) and perhaps also to the physicochemical characteristics of the drug-cell membrane-receptor interaction. The pharmacodynamic profile of the drug in hypertensive patients is consistent with the disposition of the drug. After single doses, blood pressure decreases gradually over 4-8 h and may slowly return to baseline over 24-72 h. No change in heart rate is noted after the dose as the onset is gradual and physiological reflexes are not activated. During chronic, oral, once-daily dosing blood pressure is decreased from pretreatment baseline with little fluctuation over the 24-hour dose interval. Discontinuation of amlodipine treatment results in a slow return of blood pressure to baseline over 7-10 days, with no evidence of a 'rebound' effect. Amlodipine is a low-clearance, dihydropyridine calcium antagonist which is effective for the treatment of hypertension and angina pectoris with once-daily dosing.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534713     DOI: 10.1159/000175050

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  16 in total

Review 1.  Pharmacological interventions into the renin-angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering.

Authors:  Rainer Düsing
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-04-27

2.  L-type Ca2+ channel blockers promote vascular remodeling through activation of STIM proteins.

Authors:  Martin T Johnson; Aparna Gudlur; Xuexin Zhang; Ping Xin; Scott M Emrich; Ryan E Yoast; Raphael Courjaret; Robert M Nwokonko; Wei Li; Nadine Hempel; Khaled Machaca; Donald L Gill; Patrick G Hogan; Mohamed Trebak
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-08       Impact factor: 11.205

3.  Bioavailability study of fixed-dose tablet versus capsule formulation of amlodipine plus benazepril: A randomized, single-dose, two-sequence, two-period, open-label, crossover study in healthy volunteers.

Authors:  Kuo-Liong Chien; Chia-Lun Chao; Ta-Cheng Su
Journal:  Curr Ther Res Clin Exp       Date:  2005-03

Review 4.  Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial.

Authors:  Tianjing Ren; Xu Zhu; Natalie M Jusko; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-08-30       Impact factor: 2.410

5.  Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. The Belgian Collaborative Study Group.

Authors:  J M Detry; P Block; G De Backer; J P Degaute
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

6.  A randomized controlled trial on the blood pressure-lowering effect of amlodipine and nifedipine-GITS in sustained hypertension.

Authors:  Qi-Fang Huang; Chang-Sheng Sheng; Yan Li; Yu Dou; Mei-Sheng Zheng; Zhi-Ming Zhu; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-04-11       Impact factor: 3.738

7.  Prolonged Refractory Hypotension following Combined Amlodipine and Losartan Ingestion Responsive to Metaraminol.

Authors:  James O M Plumb; Craig Stewart; Michael Eddleston; Thearina de Beer
Journal:  Case Rep Med       Date:  2011-05-12

Review 8.  Amlodipine as an antiischemic drug is superior to long acting nitrates.

Authors:  Goran P Koraćević; Sonja S Dakić; Radmila M Veličković-Radovanović; Svetlana R Apostolović; Nebojša H Krstić; Ivan S Tasić; Marija D Zdravković; Nebojša M Antonijević; Goran N Damnjanović; Tomislav L Kostić
Journal:  Open Med (Wars)       Date:  2014-11-03

9.  Simultaneous determination of telmisartan and amlodipine in human plasma by LC-MS/MS and its application in a human pharmacokinetic study.

Authors:  Vasu Babu Ravi; Jaswanth Kumar Inamadugu; Nageswara Rao Pilli; Vudagandla Sreenivasulu; Venkateswarlu Ponneri
Journal:  J Pharm Anal       Date:  2012-04-04

10.  Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes.

Authors:  Hassan Fares; James J DiNicolantonio; James H O'Keefe; Carl J Lavie
Journal:  Open Heart       Date:  2016-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.